Amicus Therapeutics

News
Amicus_Therapeutics_logo

CHMP backs Amicus' therapy for Pompe disease

Amicus Therapeutics could be just weeks away from getting EU approval for its new Pompe disease therapy Pombiliti after getting a positive opinion on the drug from the EMA's human medicines

News
galafold

Amicus' oral Fabry disease drug approved in US

Amicus Therapeutics’ first oral drug for the rare condition Fabry disease has been approved by the FDA, giving patients an alternative to conventional injected enzyme replacement therapy.